Document is current
Any future updates will be listed below
-
Authors
Karimzadeh, Amir
Hansen, Kimberley
Hein, Stefan
Haller, Bernhard
Heck, Matthias M.
Tauber, Robert
D`Alessandria, Calogero
Eiber, Matthias
Rauscher, Isabel
-
Funding
Funding for this research was provided by:
Klinikum rechts der Isar der Technischen Universität München
- License Information
-
More Information
Article History
Received: 22 January 2025
Accepted: 6 March 2025
First Online: 19 May 2025
Declarations
:
: The institutional ethics committee of the Technical University of Munich approved this retrospective analysis under the reference number 115/18S. We certify that the study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.
: Not applicable.
: ME&IR report fees from Blue Earth Diagnostics Ltd. (consultant, research funding). ME reports fees from Novartis/AAA (consultant, speaker), Telix (consultant), Bayer (consultant, research funding), RayzeBio (consultant), Point Biopharma (consultant), Eckert-Ziegler (speaker), ABX GmbH (speaker) and Janssen Pharmaceuticals (consultant, speakers bureau), Parexel (image review) and Bioclinica (image review) outside the submitted work and a patent application for rhPSMA. He and other inventors are entitled to royalties on sales of 18F-flotufolastat. RT: Advisory boards, speaking fees; travel support, conference access; author fees; shares: Astellas, AstraZeneca, Bayer, BMS, Eisai, EUSA, Ipsen, Janssen, Merck, MSD, Novartis, Orion, Philogen, Roche, Sanofi, Thieme. No other potential conflicts of interest relevant to this article exist.
